The approval makes Ogluo™ Europe’s first ready-to-use liquid glucagon for rescuing diabetic patients from severe hypoglycaemic events.
List view / Grid view
The EMA's human medicines committee has released its results for the December meeting, suggesting which therapies should receive marketing authorisation.
Marketing authorisation in the EU for Baqsimi, the first non-injectable treatment for very low levels of blood sugar, has been recommended by an EMA committee.
Phase I trial results for ZP4207 support its further development as a rescue treatment for severe hypoglycaemia
Zealand has announced results from a clinical Phase I trial with a single-dose version of its novel, stable glucagon analogue, ZP4207.